Journal Information
Share
Share
Download PDF
More article options
Visits
113
Erratum
DOI: 10.1016/j.pulmoe.2018.10.001
Open Access
Erratum to “Clinical and molecular markers in COPD” [Pulmonology 24 (4) (2018) 250–259]
Visits
113
I. Gonçalvesa, M.J. Guimarãesb, M. van Zellerc, F. Menezesd, J. Moitae, P. Simãof,
Corresponding author
med2514@ulsm.min-saude.pt

Corresponding author.
, on behalf of the GI DPOC-Grupo de Interesse na Doença Pulmonar Obstrutiva Crónica
a Pulmonology Department, Hospital Santa Marta, Lisboa, Portugal
b Pulmonology Department, Hospital Senhora da Oliveira, Guimarães, Portugal
c Pulmonology Department, Centro Hospitalar de São João, Faculty of Medicine, University of Porto, Porto, Portugal
d Pulmonology Department, Hospital Garcia de Horta, Lisboa, Portugal
e General Hospital, Coimbra University Hospital Center, Portugal
f Pulmonology Department, Hospital Pedro Hispano, Matosinhos, Portugal
Related content
Pulmonol.2018;24:250-910.1016/j.pulmoe.2018.02.005
I. Gonçalves, M.J. Guimarães, M. van Zeller, F. Menezes, J. Moita, P. Simão
This item has received
113
Visits

Under a Creative Commons license
Article information
Full Text

The publisher regrets to inform that the article “Clinical and molecular markers in COPD”, published in Pulmonol. 2018;24(4):250–259, has been published with the following information missing:

Conflict of interest

IG declares to have received speaking fees from Novartis, AstraZeneca, Menarini and GSK. MJG declares to have received speaking fees from Genzyme, GSK, Novartis, A. Menarini, Philips, Vitalaire, Praxair and Linde, and to be an Advisory Board member of the Resmed iCARE group. MvZ declares to have received speaking fees from Novartis, Boehringer Ingelheim, AstraZeneca, Teva Pharma, Tecnifar, Praxair and Vitalaire. FM declares to have received speaking fees from Novartis, AstraZeneca, Menarini, Mundipharma, TEVA and Boehringer Ingelheim. JM declares to have received speaking fees from GSK, Novartis, AstraZeneca, Menarini, Mundipharma and Boehringer Ingelheim, and to be an Advisory Board member of GSK. PS declares to have received speaking fees from Novartis Farma, Boehringer Ingelheim, Mundipharma, AstraZeneca and Linde Saúde.

Role of funding source

Funding for this paper was provided by Novartis Portugal. Funding was used to access all necessary scientific bibliography and cover meeting expenses. Novartis Portugal had no role in the collection, analysis and interpretation of data, in the writing of the paper and in the decision to submit the paper for publication.

The online version of the article has been corrected and the publisher would like to apologize for any inconvenience caused.

Pulmonology

Subscribe to our Newsletter

Article options
Tools
Cookies policy
To improve our services and products, we use cookies (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here.

Are you a health professional able to prescribe or dispense drugs?